Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
215 studies found for:    PCI-32765
Show Display Options
Rank Status Study
1 Completed A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants
Condition: Healthy Participants
Interventions: Drug: PCI-32765;   Drug: Rifampin
2 Completed A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
Condition: Recurrent Mature B-cell Neoplasms
Intervention: Drug: PCI-32765
3 Active, not recruiting Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Condition: Leukemia
Interventions: Other: Heavy Water (2H2O);   Drug: PCI-32765
4 Completed A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: PCI-32765
5 Completed A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
6 Active, not recruiting Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: PCI-32765
7 Completed A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants
Condition: Healthy Volunteer
Interventions: Drug: PCI-32765 (Treatment A);   Drug: PCI-32765 (Treatment B);   Drug: PCI-32765 (Treatment C);   Drug: 13C6 PCI-32765 (reference)
8 Completed
Has Results
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
9 Enrolling by invitation A Long-term Extension Study of PCI-32765 (Ibrutinib)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B-cell Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
10 Completed
Has Results
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Condition: Mantle Cell Lymphoma
Intervention: Drug: PCI-32765
11 Enrolling by invitation Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Diffuse Well-differentiated Lymphocytic Lymphoma;   B Cell Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin's Lymphoma;   Waldenstrom Macroglobulinemia;   Burkitt Lymphoma;   B-Cell Diffuse Lymphoma
Intervention: Drug: PCI-32765
12 Completed
Has Results
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell B-lymphoma
Intervention: Drug: ibrutinib
13 Completed A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
Condition: Healthy Volunteer
Interventions: Drug: Treatment A: PCI-32765;   Drug: Treatment B: PCI-32765
14 Completed A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
Condition: Healthy Participants
Intervention: Drug: Ibrutinib
15 Completed Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Conditions: B-Cell Lymphoma;   B-Cell Leukemia
Intervention: Drug: PCI-32765
16 Active, not recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
17 Completed
Has Results
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Prolymphocyctic Leukemia;   Richter's Transformation
Interventions: Drug: PCI-32765;   Drug: ofatumumab
18 Completed
Has Results
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
19 Completed A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765
Condition: Healthy Volunteers
Interventions: Drug: Sequence 1: PCI-32765;   Drug: Sequence 2: PCI-32765;   Drug: Sequence 3: PCI-32765;   Drug: Sequence 4: PCI-32765;   Drug: Sequence 5: PCI-32765
20 Active, not recruiting Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Behavioral: Phone Calls

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.